Medical Developments International Limited
Medical Developments International Limited MVP.AX Peers
See (MVP.AX) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| MVP.AX | A$0.62 | N/A | 69.8M | -1.82 | -A$0.34 | N/A |
| CAU.AX | A$0.54 | N/A | 300.5M | -16.88 | -A$0.03 | N/A |
| AFP.AX | A$2.60 | +4.00% | 272.7M | 26.00 | A$0.10 | +0.59% |
| PBP.AX | A$2.98 | -0.33% | 242.3M | 29.80 | A$0.10 | N/A |
| LV1.AX | A$0.92 | N/A | 144.1M | 3.05 | A$0.30 | N/A |
| VLS.AX | A$2.00 | +4.17% | 108.9M | 12.50 | A$0.16 | +5.21% |
| IHL.AX | A$0.04 | -10.87% | 65.1M | -0.03 | -A$1.30 | N/A |
| ANP.AX | A$0.06 | -4.92% | 52.3M | -2.90 | -A$0.02 | N/A |
| VIT.AX | A$0.07 | +1.47% | 45.7M | 6.90 | A$0.01 | N/A |
| IDT.AX | A$0.10 | +3.09% | 42.2M | -10.00 | -A$0.01 | N/A |
Stock Comparison
MVP.AX vs CAU.AX Comparison
MVP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MVP.AX stands at 69.8M. In comparison, CAU.AX has a market cap of 300.5M. Regarding current trading prices, MVP.AX is priced at A$0.62, while CAU.AX trades at A$0.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MVP.AX currently has a P/E ratio of -1.82, whereas CAU.AX's P/E ratio is -16.88. In terms of profitability, MVP.AX's ROE is -0.59%, compared to CAU.AX's ROE of +0.34%. Regarding short-term risk, MVP.AX is less volatile compared to CAU.AX. This indicates potentially lower risk in terms of short-term price fluctuations for MVP.AX.
MVP.AX vs AFP.AX Comparison
MVP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MVP.AX stands at 69.8M. In comparison, AFP.AX has a market cap of 272.7M. Regarding current trading prices, MVP.AX is priced at A$0.62, while AFP.AX trades at A$2.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MVP.AX currently has a P/E ratio of -1.82, whereas AFP.AX's P/E ratio is 26.00. In terms of profitability, MVP.AX's ROE is -0.59%, compared to AFP.AX's ROE of +0.14%. Regarding short-term risk, MVP.AX is more volatile compared to AFP.AX. This indicates potentially higher risk in terms of short-term price fluctuations for MVP.AX.
MVP.AX vs PBP.AX Comparison
MVP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MVP.AX stands at 69.8M. In comparison, PBP.AX has a market cap of 242.3M. Regarding current trading prices, MVP.AX is priced at A$0.62, while PBP.AX trades at A$2.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MVP.AX currently has a P/E ratio of -1.82, whereas PBP.AX's P/E ratio is 29.80. In terms of profitability, MVP.AX's ROE is -0.59%, compared to PBP.AX's ROE of +0.13%. Regarding short-term risk, MVP.AX is more volatile compared to PBP.AX. This indicates potentially higher risk in terms of short-term price fluctuations for MVP.AX.
MVP.AX vs LV1.AX Comparison
MVP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MVP.AX stands at 69.8M. In comparison, LV1.AX has a market cap of 144.1M. Regarding current trading prices, MVP.AX is priced at A$0.62, while LV1.AX trades at A$0.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MVP.AX currently has a P/E ratio of -1.82, whereas LV1.AX's P/E ratio is 3.05. In terms of profitability, MVP.AX's ROE is -0.59%, compared to LV1.AX's ROE of -4.96%. Regarding short-term risk, MVP.AX is more volatile compared to LV1.AX. This indicates potentially higher risk in terms of short-term price fluctuations for MVP.AX.
MVP.AX vs VLS.AX Comparison
MVP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MVP.AX stands at 69.8M. In comparison, VLS.AX has a market cap of 108.9M. Regarding current trading prices, MVP.AX is priced at A$0.62, while VLS.AX trades at A$2.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MVP.AX currently has a P/E ratio of -1.82, whereas VLS.AX's P/E ratio is 12.50. In terms of profitability, MVP.AX's ROE is -0.59%, compared to VLS.AX's ROE of +0.17%. Regarding short-term risk, MVP.AX is more volatile compared to VLS.AX. This indicates potentially higher risk in terms of short-term price fluctuations for MVP.AX.
MVP.AX vs IHL.AX Comparison
MVP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MVP.AX stands at 69.8M. In comparison, IHL.AX has a market cap of 65.1M. Regarding current trading prices, MVP.AX is priced at A$0.62, while IHL.AX trades at A$0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MVP.AX currently has a P/E ratio of -1.82, whereas IHL.AX's P/E ratio is -0.03. In terms of profitability, MVP.AX's ROE is -0.59%, compared to IHL.AX's ROE of -0.33%. Regarding short-term risk, MVP.AX is less volatile compared to IHL.AX. This indicates potentially lower risk in terms of short-term price fluctuations for MVP.AX.
MVP.AX vs ANP.AX Comparison
MVP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MVP.AX stands at 69.8M. In comparison, ANP.AX has a market cap of 52.3M. Regarding current trading prices, MVP.AX is priced at A$0.62, while ANP.AX trades at A$0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MVP.AX currently has a P/E ratio of -1.82, whereas ANP.AX's P/E ratio is -2.90. In terms of profitability, MVP.AX's ROE is -0.59%, compared to ANP.AX's ROE of -0.73%. Regarding short-term risk, MVP.AX is less volatile compared to ANP.AX. This indicates potentially lower risk in terms of short-term price fluctuations for MVP.AX.
MVP.AX vs VIT.AX Comparison
MVP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MVP.AX stands at 69.8M. In comparison, VIT.AX has a market cap of 45.7M. Regarding current trading prices, MVP.AX is priced at A$0.62, while VIT.AX trades at A$0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MVP.AX currently has a P/E ratio of -1.82, whereas VIT.AX's P/E ratio is 6.90. In terms of profitability, MVP.AX's ROE is -0.59%, compared to VIT.AX's ROE of +0.05%. Regarding short-term risk, MVP.AX is more volatile compared to VIT.AX. This indicates potentially higher risk in terms of short-term price fluctuations for MVP.AX.
MVP.AX vs IDT.AX Comparison
MVP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MVP.AX stands at 69.8M. In comparison, IDT.AX has a market cap of 42.2M. Regarding current trading prices, MVP.AX is priced at A$0.62, while IDT.AX trades at A$0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MVP.AX currently has a P/E ratio of -1.82, whereas IDT.AX's P/E ratio is -10.00. In terms of profitability, MVP.AX's ROE is -0.59%, compared to IDT.AX's ROE of -0.19%. Regarding short-term risk, MVP.AX is more volatile compared to IDT.AX. This indicates potentially higher risk in terms of short-term price fluctuations for MVP.AX.
MVP.AX vs LGP.AX Comparison
MVP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MVP.AX stands at 69.8M. In comparison, LGP.AX has a market cap of 33.4M. Regarding current trading prices, MVP.AX is priced at A$0.62, while LGP.AX trades at A$0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MVP.AX currently has a P/E ratio of -1.82, whereas LGP.AX's P/E ratio is 11.00. In terms of profitability, MVP.AX's ROE is -0.59%, compared to LGP.AX's ROE of -0.12%. Regarding short-term risk, MVP.AX is more volatile compared to LGP.AX. This indicates potentially higher risk in terms of short-term price fluctuations for MVP.AX.
MVP.AX vs CPH.AX Comparison
MVP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MVP.AX stands at 69.8M. In comparison, CPH.AX has a market cap of 23.1M. Regarding current trading prices, MVP.AX is priced at A$0.62, while CPH.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MVP.AX currently has a P/E ratio of -1.82, whereas CPH.AX's P/E ratio is -0.45. In terms of profitability, MVP.AX's ROE is -0.59%, compared to CPH.AX's ROE of -1.31%. Regarding short-term risk, MVP.AX is more volatile compared to CPH.AX. This indicates potentially higher risk in terms of short-term price fluctuations for MVP.AX.
MVP.AX vs AGH.AX Comparison
MVP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MVP.AX stands at 69.8M. In comparison, AGH.AX has a market cap of 21.4M. Regarding current trading prices, MVP.AX is priced at A$0.62, while AGH.AX trades at A$0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MVP.AX currently has a P/E ratio of -1.82, whereas AGH.AX's P/E ratio is -0.65. In terms of profitability, MVP.AX's ROE is -0.59%, compared to AGH.AX's ROE of -51.14%. Regarding short-term risk, MVP.AX is less volatile compared to AGH.AX. This indicates potentially lower risk in terms of short-term price fluctuations for MVP.AX.
MVP.AX vs PXS.AX Comparison
MVP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MVP.AX stands at 69.8M. In comparison, PXS.AX has a market cap of 20.2M. Regarding current trading prices, MVP.AX is priced at A$0.62, while PXS.AX trades at A$0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MVP.AX currently has a P/E ratio of -1.82, whereas PXS.AX's P/E ratio is -1.40. In terms of profitability, MVP.AX's ROE is -0.59%, compared to PXS.AX's ROE of -1.12%. Regarding short-term risk, MVP.AX is more volatile compared to PXS.AX. This indicates potentially higher risk in terms of short-term price fluctuations for MVP.AX.
MVP.AX vs NXS.AX Comparison
MVP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MVP.AX stands at 69.8M. In comparison, NXS.AX has a market cap of 19.9M. Regarding current trading prices, MVP.AX is priced at A$0.62, while NXS.AX trades at A$0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MVP.AX currently has a P/E ratio of -1.82, whereas NXS.AX's P/E ratio is -1.13. In terms of profitability, MVP.AX's ROE is -0.59%, compared to NXS.AX's ROE of -2.01%. Regarding short-term risk, MVP.AX is less volatile compared to NXS.AX. This indicates potentially lower risk in terms of short-term price fluctuations for MVP.AX.
MVP.AX vs MXC.AX Comparison
MVP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MVP.AX stands at 69.8M. In comparison, MXC.AX has a market cap of 18.4M. Regarding current trading prices, MVP.AX is priced at A$0.62, while MXC.AX trades at A$0.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MVP.AX currently has a P/E ratio of -1.82, whereas MXC.AX's P/E ratio is -0.13. In terms of profitability, MVP.AX's ROE is -0.59%, compared to MXC.AX's ROE of +26.60%. Regarding short-term risk, MVP.AX is less volatile compared to MXC.AX. This indicates potentially lower risk in terms of short-term price fluctuations for MVP.AX.
MVP.AX vs AC8.AX Comparison
MVP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MVP.AX stands at 69.8M. In comparison, AC8.AX has a market cap of 17.6M. Regarding current trading prices, MVP.AX is priced at A$0.62, while AC8.AX trades at A$0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MVP.AX currently has a P/E ratio of -1.82, whereas AC8.AX's P/E ratio is -0.67. In terms of profitability, MVP.AX's ROE is -0.59%, compared to AC8.AX's ROE of -0.61%. Regarding short-term risk, MVP.AX is more volatile compared to AC8.AX. This indicates potentially higher risk in terms of short-term price fluctuations for MVP.AX.
MVP.AX vs ECS.AX Comparison
MVP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MVP.AX stands at 69.8M. In comparison, ECS.AX has a market cap of 13M. Regarding current trading prices, MVP.AX is priced at A$0.62, while ECS.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MVP.AX currently has a P/E ratio of -1.82, whereas ECS.AX's P/E ratio is N/A. In terms of profitability, MVP.AX's ROE is -0.59%, compared to ECS.AX's ROE of -0.05%. Regarding short-term risk, MVP.AX is more volatile compared to ECS.AX. This indicates potentially higher risk in terms of short-term price fluctuations for MVP.AX.
MVP.AX vs PER.AX Comparison
MVP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MVP.AX stands at 69.8M. In comparison, PER.AX has a market cap of 10.9M. Regarding current trading prices, MVP.AX is priced at A$0.62, while PER.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MVP.AX currently has a P/E ratio of -1.82, whereas PER.AX's P/E ratio is -0.50. In terms of profitability, MVP.AX's ROE is -0.59%, compared to PER.AX's ROE of -1.23%. Regarding short-term risk, MVP.AX is less volatile compared to PER.AX. This indicates potentially lower risk in terms of short-term price fluctuations for MVP.AX.
MVP.AX vs IVX.AX Comparison
MVP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MVP.AX stands at 69.8M. In comparison, IVX.AX has a market cap of 10.2M. Regarding current trading prices, MVP.AX is priced at A$0.62, while IVX.AX trades at A$0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MVP.AX currently has a P/E ratio of -1.82, whereas IVX.AX's P/E ratio is -1.09. In terms of profitability, MVP.AX's ROE is -0.59%, compared to IVX.AX's ROE of -0.49%. Regarding short-term risk, MVP.AX is more volatile compared to IVX.AX. This indicates potentially higher risk in terms of short-term price fluctuations for MVP.AX.
MVP.AX vs HGV.AX Comparison
MVP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MVP.AX stands at 69.8M. In comparison, HGV.AX has a market cap of 10.1M. Regarding current trading prices, MVP.AX is priced at A$0.62, while HGV.AX trades at A$0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MVP.AX currently has a P/E ratio of -1.82, whereas HGV.AX's P/E ratio is -2.40. In terms of profitability, MVP.AX's ROE is -0.59%, compared to HGV.AX's ROE of -0.01%. Regarding short-term risk, MVP.AX is more volatile compared to HGV.AX. This indicates potentially higher risk in terms of short-term price fluctuations for MVP.AX.
MVP.AX vs CAN.AX Comparison
MVP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MVP.AX stands at 69.8M. In comparison, CAN.AX has a market cap of 8.7M. Regarding current trading prices, MVP.AX is priced at A$0.62, while CAN.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MVP.AX currently has a P/E ratio of -1.82, whereas CAN.AX's P/E ratio is -0.14. In terms of profitability, MVP.AX's ROE is -0.59%, compared to CAN.AX's ROE of -4.70%. Regarding short-term risk, MVP.AX is less volatile compared to CAN.AX. This indicates potentially lower risk in terms of short-term price fluctuations for MVP.AX.
MVP.AX vs EPN.AX Comparison
MVP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MVP.AX stands at 69.8M. In comparison, EPN.AX has a market cap of 8.3M. Regarding current trading prices, MVP.AX is priced at A$0.62, while EPN.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MVP.AX currently has a P/E ratio of -1.82, whereas EPN.AX's P/E ratio is -2.40. In terms of profitability, MVP.AX's ROE is -0.59%, compared to EPN.AX's ROE of -0.13%. Regarding short-term risk, MVP.AX is less volatile compared to EPN.AX. This indicates potentially lower risk in terms of short-term price fluctuations for MVP.AX.
MVP.AX vs EOF.AX Comparison
MVP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MVP.AX stands at 69.8M. In comparison, EOF.AX has a market cap of 7.3M. Regarding current trading prices, MVP.AX is priced at A$0.62, while EOF.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MVP.AX currently has a P/E ratio of -1.82, whereas EOF.AX's P/E ratio is -0.50. In terms of profitability, MVP.AX's ROE is -0.59%, compared to EOF.AX's ROE of -0.51%. Regarding short-term risk, MVP.AX is less volatile compared to EOF.AX. This indicates potentially lower risk in terms of short-term price fluctuations for MVP.AX.
MVP.AX vs CGB.AX Comparison
MVP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MVP.AX stands at 69.8M. In comparison, CGB.AX has a market cap of 5.6M. Regarding current trading prices, MVP.AX is priced at A$0.62, while CGB.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MVP.AX currently has a P/E ratio of -1.82, whereas CGB.AX's P/E ratio is -0.70. In terms of profitability, MVP.AX's ROE is -0.59%, compared to CGB.AX's ROE of +0.00%. Regarding short-term risk, MVP.AX is more volatile compared to CGB.AX. This indicates potentially higher risk in terms of short-term price fluctuations for MVP.AX.
MVP.AX vs BOD.AX Comparison
MVP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MVP.AX stands at 69.8M. In comparison, BOD.AX has a market cap of 4.3M. Regarding current trading prices, MVP.AX is priced at A$0.62, while BOD.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MVP.AX currently has a P/E ratio of -1.82, whereas BOD.AX's P/E ratio is -0.40. In terms of profitability, MVP.AX's ROE is -0.59%, compared to BOD.AX's ROE of +0.66%. Regarding short-term risk, MVP.AX is less volatile compared to BOD.AX. This indicates potentially lower risk in terms of short-term price fluctuations for MVP.AX.
MVP.AX vs SCU.AX Comparison
MVP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MVP.AX stands at 69.8M. In comparison, SCU.AX has a market cap of 3.9M. Regarding current trading prices, MVP.AX is priced at A$0.62, while SCU.AX trades at A$0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MVP.AX currently has a P/E ratio of -1.82, whereas SCU.AX's P/E ratio is N/A. In terms of profitability, MVP.AX's ROE is -0.59%, compared to SCU.AX's ROE of -0.66%. Regarding short-term risk, MVP.AX is less volatile compared to SCU.AX. This indicates potentially lower risk in terms of short-term price fluctuations for MVP.AX.
MVP.AX vs EXL.AX Comparison
MVP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MVP.AX stands at 69.8M. In comparison, EXL.AX has a market cap of 2.9M. Regarding current trading prices, MVP.AX is priced at A$0.62, while EXL.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MVP.AX currently has a P/E ratio of -1.82, whereas EXL.AX's P/E ratio is -1.30. In terms of profitability, MVP.AX's ROE is -0.59%, compared to EXL.AX's ROE of -0.20%. Regarding short-term risk, MVP.AX is less volatile compared to EXL.AX. This indicates potentially lower risk in terms of short-term price fluctuations for MVP.AX.
MVP.AX vs TSN.AX Comparison
MVP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MVP.AX stands at 69.8M. In comparison, TSN.AX has a market cap of 1.4M. Regarding current trading prices, MVP.AX is priced at A$0.62, while TSN.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MVP.AX currently has a P/E ratio of -1.82, whereas TSN.AX's P/E ratio is -0.33. In terms of profitability, MVP.AX's ROE is -0.59%, compared to TSN.AX's ROE of -0.97%. Regarding short-term risk, MVP.AX is more volatile compared to TSN.AX. This indicates potentially higher risk in terms of short-term price fluctuations for MVP.AX.